Who are Ocular Therapeutix, Inc.'s main suppliers?

Ocular Therapeutix, Inc. (OCUL) key suppliers include: CELG-RI, CELG-RI, EyePoint, Inc., Opus Genetics, Inc., Kalaris Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/OCUL.

Who are Ocular Therapeutix, Inc.'s major customers?

Ocular Therapeutix, Inc. (OCUL) key customers include: CUSTOMER-1, CUSTOMER-2, CUSTOMER-3, CELG-RI, CELG-RI and 5 more. View the full customer network at chainsifter.com/chain/OCUL.

What sector is Ocular Therapeutix, Inc. in?

Ocular Therapeutix, Inc. (OCUL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Ocular Therapeutix, Inc. Supplier List (OCUL): 5 Verified Suppliers

5Suppliers

10Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Ocular Therapeutix, Inc. (OCUL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

2Distinct source URLs

6High confidence

0.758Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Ocular Therapeutix, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CELG-RI	CELG-RI	72%	uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the …
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a s…
EYPT	EyePoint, Inc.	72%	Reciprocal relationship from EYPT graph: nications by third parties, including competitors, whether accurate or inaccurate, that may be perceived as negative with respect to us, our business, our pro…
IRD	Opus Genetics, Inc.	72%	Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or mor…
KLRS	Kalaris Therapeutics, Inc.	72%	Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There ar…

Ocular Therapeutix, Inc. Customers

Ticker	Name	Confidence	Evidence
CUSTOMER-1	CUSTOMER-1	90%	Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 1 38 % 39 %
CUSTOMER-2	CUSTOMER-2	90%	Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 2 28 24
CUSTOMER-3	CUSTOMER-3	90%	Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 3 7 8
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a s…
CELG-RI	CELG-RI	72%	uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the …
IRD	Opus Genetics, Inc.	72%	Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or mor…
AFFAMED-THERAPEUTICS-LIMITED	AFFAMED-THERAPEUTICS-LIMITED	62%	. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses a…
BARINGS-FINANCE-LLC	BARINGS-FINANCE-LLC	62%	. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses a…
BOSTON-IMAGE-READING-CENTER-LLC	BOSTON-IMAGE-READING-CENTER-LLC	62%	derally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company is dependent…
INCEPT-LLC	INCEPT-LLC	62%	e, laboratory and manufacturing space in Bedford, Massachusetts, which expire in July 2027, July 2028, and March 2031, and leases of equipment that expire between 2026 and 2028. In January 2026, we e…

Ocular Therapeutix, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
OCUL-DEBT	Debt stack $18.0M	90%	Market cache reports total debt of $18.0M.
OCUL-DEBT-11486	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Ocular Therapeutix, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Ocular Therapeutix, Inc..

Ocular Therapeutix, Inc. Ownership

Holder	Name	Confidence	Evidence
OCUL-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 272 tracked holders.

Ocular Therapeutix, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
IRD	Opus Genetics, Inc.	100.00	1	['customer', 'supplier']
NVSEF	Novartis AG	100.00	2
OTLK	Outlook Therapeutics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	100.00	1	['customer', 'supplier']
ANIP	ANI Pharmaceuticals, Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
MYGN	Myriad Genetics, Inc.	50.00	2
PCSA	Processa Pharmaceuticals, Inc.	50.00	2
SMMT	Summit Therapeutics Inc.	50.00	2
RNTX	Rein Therapeutics Inc.	50.00	2
UCSD	UCSD	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
CUE	Cue Biopharma, Inc.	50.00	2
ORANY	ORANGE	50.00	2
GNLX	Genelux Corporation	50.00	2
TRVI	Trevi Therapeutics, Inc.	50.00	2
INAB	IN8bio, Inc.	50.00	2
HOWL	Werewolf Therapeutics, Inc.	50.00	2

Ocular Therapeutix, Inc. Supply Chain